[go: up one dir, main page]

HUP0100437A3 - Therapeutic formulation for administering tolterodine with controlled release - Google Patents

Therapeutic formulation for administering tolterodine with controlled release

Info

Publication number
HUP0100437A3
HUP0100437A3 HU0100437A HUP0100437A HUP0100437A3 HU P0100437 A3 HUP0100437 A3 HU P0100437A3 HU 0100437 A HU0100437 A HU 0100437A HU P0100437 A HUP0100437 A HU P0100437A HU P0100437 A3 HUP0100437 A3 HU P0100437A3
Authority
HU
Hungary
Prior art keywords
controlled release
therapeutic formulation
tolterodine
administering
administering tolterodine
Prior art date
Application number
HU0100437A
Other languages
English (en)
Original Assignee
Pharmacia And Upjohn Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26663376&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0100437(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from SE9802864A external-priority patent/SE9802864D0/xx
Priority claimed from SE9803871A external-priority patent/SE9803871D0/xx
Application filed by Pharmacia And Upjohn Ab filed Critical Pharmacia And Upjohn Ab
Publication of HUP0100437A2 publication Critical patent/HUP0100437A2/hu
Publication of HUP0100437A3 publication Critical patent/HUP0100437A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
HU0100437A 1998-08-27 1999-08-26 Therapeutic formulation for administering tolterodine with controlled release HUP0100437A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9802864A SE9802864D0 (sv) 1998-08-27 1998-08-27 Transdermally administered tolterodine as antimuscarinic agent for the treatment of overactive bladder
SE9803871A SE9803871D0 (sv) 1998-11-11 1998-11-11 Therapeutic method and formulation

Publications (2)

Publication Number Publication Date
HUP0100437A2 HUP0100437A2 (hu) 2002-05-29
HUP0100437A3 true HUP0100437A3 (en) 2002-08-28

Family

ID=26663376

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0100437A HUP0100437A3 (en) 1998-08-27 1999-08-26 Therapeutic formulation for administering tolterodine with controlled release

Country Status (31)

Country Link
US (1) US6770295B1 (hu)
EP (2) EP2153825A1 (hu)
CN (1) CN1239152C (hu)
AP (1) AP1529A (hu)
AR (1) AR029311A1 (hu)
AT (1) ATE487471T1 (hu)
AU (1) AU745190B2 (hu)
BG (1) BG65168B1 (hu)
CA (1) CA2311755C (hu)
CY (1) CY1111088T1 (hu)
CZ (1) CZ302630B6 (hu)
DE (1) DE69942928D1 (hu)
DK (1) DK1039882T3 (hu)
EA (1) EA002720B1 (hu)
GE (1) GEP20043354B (hu)
HK (1) HK1034664A1 (hu)
HU (1) HUP0100437A3 (hu)
ID (1) ID25824A (hu)
IL (1) IL136294A (hu)
IS (1) IS2976B (hu)
ME (1) ME00850B (hu)
MY (1) MY127946A (hu)
NO (1) NO329830B1 (hu)
NZ (1) NZ504618A (hu)
OA (1) OA11636A (hu)
PT (1) PT1039882E (hu)
SI (1) SI1039882T1 (hu)
SK (1) SK287111B6 (hu)
TR (1) TR200001998T1 (hu)
UA (1) UA72882C2 (hu)
WO (1) WO2000012069A1 (hu)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0957073A1 (en) 1998-05-12 1999-11-17 Schwarz Pharma Ag Novel derivatives of 3,3-diphenylpropylamines
DE19922662C1 (de) 1999-05-18 2000-12-28 Sanol Arznei Schwarz Gmbh Transdermales therapeutisches System (TTS) Tolterodin enthaltend
DE19932651A1 (de) * 1999-07-13 2001-01-18 Hexal Ag Transdermales therapeutisches System zur Anwendung von Tolterodin
DE60021749T2 (de) * 1999-11-11 2006-04-20 Pfizer Health Ab Pharmazeutische formulierung enthaltend tolterodin sowie ihre verwendung
DE10149674A1 (de) 2001-10-09 2003-04-24 Apogepha Arzneimittel Gmbh Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung
US8329217B2 (en) 2001-11-06 2012-12-11 Osmotica Kereskedelmi Es Szolgaltato Kft Dual controlled release dosage form
US20030185882A1 (en) 2001-11-06 2003-10-02 Vergez Juan A. Pharmaceutical compositions containing oxybutynin
CA2466336A1 (en) * 2001-11-09 2003-05-15 Ebrahim Versi Anti-muscarinic agent and estrogen-agonist for treating unstable or overactive bladder
US6773421B2 (en) 2001-12-14 2004-08-10 Kimberly-Clark Worlwide, Inc. Combination for managing the involuntary loss of bladder control
EP1424079A1 (en) * 2002-11-27 2004-06-02 Boehringer Ingelheim International GmbH Combination of a beta-3-receptor agonist and of a reuptake inhibitor of serotonin and/or norepinephrine
DE60332387D1 (de) * 2002-12-13 2010-06-10 Warner Lambert Co Alpha-2-delta-ligand zur behandlung vonsymptomen der unteren harnwege
EP1589958B2 (en) † 2003-01-22 2012-04-11 Pfizer Health AB Reduced dose of tolterodine for treating urinary disorders
DE10315917A1 (de) * 2003-04-08 2004-11-18 Schwarz Pharma Ag Hochreine Basen von 3,3-Diphenylpropylaminmonoestern
EP1635795A1 (en) * 2003-05-30 2006-03-22 Ranbaxy Laboratories, Ltd. Controlled release pharmaceutical compositions of tolterodine and processes for their preparation
WO2005046663A1 (en) 2003-11-04 2005-05-26 Shire Laboratories, Inc. Compositions of quaternary ammonium containing bioavailability enhancers
PT2210605T (pt) 2003-11-04 2017-04-24 Tcd Royalty Sub Llc Formas de dosagem única diária de tróspio
WO2005105036A1 (en) * 2004-04-28 2005-11-10 Natco Pharma Limited Controlled release mucoadhesive matrix formulation containing tolterodine and a process for its preparation
EP1629834A1 (en) † 2004-08-27 2006-03-01 KRKA, D.D., Novo Mesto Sustained release pharmaceutical composition of tolterodine
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
RU2007140348A (ru) 2005-04-06 2009-05-20 Адамас Фармасьютикалс, Инк. (Us) Способы и композиции для лечения заболеваний цнс
CN1330297C (zh) * 2005-07-04 2007-08-08 宛六一 酒石酸托特罗定软胶囊及其制备方法
KR20070012205A (ko) * 2005-07-22 2007-01-25 주식회사종근당 경시 안정성을 갖는 톨테로딘을 함유하는 제어방출형 펠렛
CA2640094C (en) 2006-02-03 2015-04-14 Proventiv Therapeutics, Llc Treating vitamin d insufficiency and deficiency with 25-hydroxyvitamin d2 and 25-hydroxyvitamin d3
EP2015735A1 (en) * 2006-04-21 2009-01-21 Synthon B.V. Tolterodine beads
EP2037936B1 (en) 2006-06-21 2014-06-11 Proventiv Therapeutics, LLC Method of treating and preventing secondary hyperparathyroidism
KR20190141269A (ko) 2007-04-25 2019-12-23 사이토크로마 인코포레이티드 비타민 ｄ 화합물과 밀랍성 담체를 포함하는 경구 조절성 방출 조성물
DK2148684T3 (da) 2007-04-25 2013-04-22 Cytochroma Inc Fremgangsmåde til behandling af vitamin D-insufficiens og -deficiens
WO2008134523A1 (en) 2007-04-25 2008-11-06 Proventiv Therapeutics, Llc Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease
CL2008001970A1 (es) * 2007-07-03 2009-03-27 Synthon Bv Perla con un nucleo de celulosa microcristalina, un recubrimiento soluble en agua con un polimero vinil pirrolidina, una capa con tolterodina y un aglutinante, y una capa de liberacion controlada con un poliacrilato; proceso para prepararla; forma de dosificacion, util en trastornos urinarios como vejiga hiperactiva.
US8486452B2 (en) * 2007-07-20 2013-07-16 Mylan Pharmaceuticals Inc. Stabilized tolterodine tartrate formulations
WO2009019599A2 (en) 2007-08-08 2009-02-12 Themis Laboratories Private Limited Extended release compositions comprising tolterodine
US20090192228A1 (en) * 2008-01-28 2009-07-30 Actavis Group Ptc Ehf Controlled-Release Tolterodine Compositions and Methods
US20090214665A1 (en) * 2008-02-26 2009-08-27 Lai Felix S Controlled Release Muscarinic Receptor Antagonist Formulation
CA2714996C (en) 2008-04-02 2020-04-07 Cytochroma Inc. Methods, compositions, uses, and kits useful for vitamin d deficiency and related disorders
TWI541246B (zh) 2008-12-08 2016-07-11 歐陸斯迪公司 二氫羥戊甲嗎啡
KR101004205B1 (ko) * 2008-12-17 2010-12-24 동아제약주식회사 유데나필 함유 서방성 제제를 제조하기 위한 제어방출 조성물
WO2011095388A1 (en) 2010-02-04 2011-08-11 Synthon Bv Tolterodine bead
KR101746204B1 (ko) * 2010-02-18 2017-06-13 에스케이케미칼주식회사 피부 투과가 개선된 톨테로딘의 경피 투여용 조성물
CN103037902A (zh) 2010-03-29 2013-04-10 赛特克罗公司 用于降低甲状旁腺水平的方法和组合物
CA2796877A1 (en) 2010-04-30 2011-11-03 Merck Sharp & Dohme Corp. Novel beta 3 adrenergic receptor agonists
DE102010024105A1 (de) * 2010-06-17 2011-12-22 Grünenthal GmbH Transdermale Verabreichung von Memantin
JP5642790B2 (ja) * 2010-08-03 2014-12-17 久光製薬株式会社 貼付剤及びその粘着力増強方法
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
GB201309654D0 (en) 2013-05-30 2013-07-17 Euro Celtique Sa Method
US10220047B2 (en) 2014-08-07 2019-03-05 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
KR20230056790A (ko) 2016-03-28 2023-04-27 옵코 아일랜드 글로벌 홀딩스 리미티드 비타민 d 치료 방법

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3598123A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US4008719A (en) * 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
SE8800207D0 (sv) 1988-01-22 1988-01-22 Kabivitrum Ab Nya aminer, deras anvendning och framstellning
US5382600A (en) * 1988-01-22 1995-01-17 Pharmacia Aktiebolag 3,3-diphenylpropylamines and pharmaceutical compositions thereof
MX9302812A (es) * 1992-05-13 1993-11-01 Alza Corp Administracion transdermica de oxibutinina.
SE9203318D0 (sv) 1992-11-06 1992-11-06 Kabi Pharmacia Ab Novel 3,3-diphenylpropylamines, their use and preparation
TW344661B (en) * 1993-11-24 1998-11-11 Lilly Co Eli Pharmaceutical composition for treatment of incontinence
AU7994694A (en) * 1994-10-21 1996-05-15 Leiras Oy Controlled release oral delivery system containing oxybutynin
US5677346A (en) * 1995-01-31 1997-10-14 Sepracor, Inc. Treating urinary incontinence using (S)-desethyloxybutynin
CA2259012C (en) 1996-07-19 2008-05-13 Gunnar Aberg S(-)-tolterodine in the treatment of urinary and gastrointestinal disorders
EP0927034A1 (en) * 1996-09-19 1999-07-07 American Home Products Corporation Method of treating urinary incontinence

Also Published As

Publication number Publication date
ME00850B (me) 2008-08-07
WO2000012069A1 (en) 2000-03-09
BG104476A (en) 2000-12-29
OA11636A (en) 2004-09-03
US6770295B1 (en) 2004-08-03
SK7492000A3 (en) 2001-02-12
AR029311A1 (es) 2003-06-25
AU745190B2 (en) 2002-03-14
AU5891899A (en) 2000-03-21
ID25824A (id) 2000-11-09
CZ20001924A3 (cs) 2001-04-11
EP2153825A1 (en) 2010-02-17
DK1039882T3 (da) 2011-01-24
DE69942928D1 (de) 2010-12-23
GEP20043354B (en) 2004-04-13
CZ302630B6 (cs) 2011-08-10
ATE487471T1 (de) 2010-11-15
IS2976B (is) 2017-07-15
UA72882C2 (uk) 2005-05-16
CA2311755C (en) 2010-03-23
NO20002977D0 (no) 2000-06-09
AP2000001823A0 (en) 2000-06-30
AP1529A (en) 2006-01-03
EP1039882B1 (en) 2010-11-10
CN1287484A (zh) 2001-03-14
MY127946A (en) 2007-01-31
IL136294A (en) 2004-02-08
TR200001998T1 (tr) 2001-01-22
NO329830B1 (no) 2011-01-03
BG65168B1 (bg) 2007-05-31
SI1039882T1 (sl) 2011-01-31
SK287111B6 (sk) 2009-12-07
HK1034664A1 (en) 2001-11-02
NO20002977L (no) 2000-06-09
EP1039882A1 (en) 2000-10-04
EA002720B1 (ru) 2002-08-29
CY1111088T1 (el) 2015-06-11
IL136294A0 (en) 2001-05-20
CA2311755A1 (en) 2000-03-09
IS5537A (is) 2000-06-15
PT1039882E (pt) 2011-01-03
HUP0100437A2 (hu) 2002-05-29
CN1239152C (zh) 2006-02-01
EA200000468A1 (ru) 2000-12-25
NZ504618A (en) 2002-09-27

Similar Documents

Publication Publication Date Title
AP2000001823A0 (en) Therapeutic formulation for administering tolterodine with controlled release
IL143496A0 (en) Controlled release formulation comprising gnrh-ii
PL342515A1 (en) Drug administering device
EP1124543A4 (en) REGULATED RELEASE FORMULATION FOR WATER-SOLUBLE DRUGS
IL132453A0 (en) Gastroretentive controlled release microspheres for improve drug delivery
HK1030363A1 (en) Noninvasive vaccination through the skin
HK1019142A1 (en) Drug composition with controlled drug release rate
GB9706318D0 (en) Therapeutic formulations
IL137186A0 (en) Device for inhaling medicament
HUP0003840A3 (en) Controlled released medical formulation
IL138192A0 (en) Controlled release oral dosage forms
EP1207852A4 (en) ORAL PHARMACEUTICALS WITH TAXED RELEASE FOR ORAL ADMINISTRATION
PL339848A1 (en) Therapeutic agent against hypephosphataemia
IL156414A0 (en) Therapeutic formulation for administering tolterodine with controlled release
GB9723999D0 (en) Therapeutic use
PL325509A1 (en) Therapeutic agent for oral administration
GB9810920D0 (en) Therapeutic use
SI1117421T1 (en) Methods for therapeutic vaccination
GB9911238D0 (en) Therapeutic use
GB2341319B (en) Use of compounds in the preparation of a medicament for the therapeutic treatment of a wasting syndrome
GB9404544D0 (en) Controlled release formulation
GB9812664D0 (en) Therapeutic use
GB9726702D0 (en) Therapeutic use
GB9812666D0 (en) Therapeutic use
GB9812612D0 (en) Therapeutic use

Legal Events

Date Code Title Description
FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished